4.8 Article

Synergistic Cancer Photochemotherapy via Layered Double Hydroxide-Based Trimodal Nanomedicine at Very Low Therapeutic Doses

期刊

ACS APPLIED MATERIALS & INTERFACES
卷 13, 期 6, 页码 7115-7126

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsami.0c23143

关键词

layered double hydroxide; multifunctional nanomedicine; simultaneous photothermal/photodynamic therapy triggered by the same NIR laser; pH-sensitive prodrug cancer chemotherapy; synergistic cancer photochemotherapy

资金

  1. Australian Research Council (ARC) Discovery Project [DP170104643, DP190103486]
  2. DECRA Fellowship [DE170100092]
  3. National Health and Medical Research Council [APP1175808]

向作者/读者索取更多资源

A novel trifunctional LDH nanosystem was developed for combined photochemotherapy of skin cancer by releasing drugs in an acid-triggered manner and generating heating and reactive oxygen species upon laser irradiation, which nearly eradicated tumor tissues with minimal side effects.
The success of cancer therapy is always accompanied by severe side effects due to the high amount of toxic antitumor drugs that off-target normal organs/tissues. Herein, we report the development of a trifunctional layered double hydroxide (LDH) nanosystem for combined photochemotherapy of skin cancer at very low therapeutic doses. This nanosystem (ICG/Cu-LDH@BSA-DOX) is composed of acid-responsive bovine serum albumin-doxorubicin prodrug (BSA-DOX) and indocyanine green (ICG)-intercalated Cu-doped LDH nanoparticle. ICG/Cu-LDH@BSA-DOX is able to release DOX in an acid-triggered manner, efficiently and simultaneously generates heating and reactive oxygen species (ROS) upon 808 nm laser irradiation, and synergistically induces apoptosis of skin cancer cells. In vivo therapeutic evaluations demonstrate that ICG/Cu-LDH@BSA-DOX nearly eradicated the tumor tissues upon one-course treatment using very low doses of therapeutic agents (0.175 mg/kg DOX, 0.5 mg/kg Cu, and 0.25 mg/kg ICG) upon very mild 808 nm laser irradiation (0.3 W/cm(2) for 2 min). This work thus provides a novel strategy to design anticancer nanomedicine for efficient combination cancer treatment with minimal side effects in clinical applications.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据